Literature DB >> 23587004

Pathway specific modulation of S1P1 receptor signalling in rat and human astrocytes.

Luke M Healy1, Graham K Sheridan, Adam J Pritchard, Aleksandra Rutkowska, Florian Mullershausen, Kumlesh K Dev.   

Abstract

BACKGROUND AND
PURPOSE: The sphingosine 1-phosphate receptor subtype 1 (S1P1R) is modulated by phosphorylated FTY720 (pFTY720), which causes S1P1R internalization preventing lymphocyte migration thus limiting autoimmune response. Studies indicate that internalized S1P1Rs continue to signal, maintaining an inhibition of cAMP, thus raising question whether the effects of pFTY720 are due to transient initial agonism, functional antagonism and/or continued signalling. To further investigate this, the current study first determined if continued S1P1R activation is pathway specific. EXPERIMENTAL APPROACH: Using human and rat astrocyte cultures, the effects of S1P1R activation on cAMP, pERK and Ca(2+) signalling was investigated. In addition, to examine the role of S1P1R redistribution on these events, a novel biologic (MNP301) that prevented pFTY720-mediated S1P1R redistribution was engineered. KEY
RESULTS: The data showed that pFTY720 induced long-lasting S1P1R redistribution and continued cAMP signalling in rat astrocytes. In contrast, pFTY720 induced a transient increase of Ca(2+) in astrocytes and subsequent antagonism of Ca(2+) signalling. Notably, while leaving pFTY720-induced cAMP signalling intact, the novel MNP301 peptide attenuated S1P1R-mediated Ca(2+) and pERK signalling in cultured rat astrocytes. CONCLUSIONS AND IMPLICATIONS: These findings suggested that pFTY720 causes continued cAMP signalling that is not dependent on S1P1R redistribution and induces functional antagonism of Ca(2+) signalling after transient stimulation. To our knowledge, this is the first report demonstrating that pFTY720 causes continued signalling in one pathway (cAMP) versus functional antagonism of another pathway (Ca(2+)) and which also suggests that redistributed S1P1Rs may have differing signalling properties from those expressed at the surface.
© 2013 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23587004      PMCID: PMC3696333          DOI: 10.1111/bph.12207

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

1.  The immune modulator FTY720 targets sphingosine 1-phosphate receptors.

Authors:  Volker Brinkmann; Michael D Davis; Christopher E Heise; Rainer Albert; Sylvain Cottens; Robert Hof; Christian Bruns; Eva Prieschl; Thomas Baumruker; Peter Hiestand; Carolyn A Foster; Markus Zollinger; Kevin R Lynch
Journal:  J Biol Chem       Date:  2002-04-19       Impact factor: 5.157

2.  Effect of growth hormone on growth failure and bone loss induced by supraphysiologic dose of glucocorticoid in rats.

Authors:  M Sato; H Dobashi; H Ohye; T Akiyama; J Kawanishi; Y Kaji; S Mori; J Takahara
Journal:  Endocr J       Date:  1999-03       Impact factor: 2.349

3.  Assessment of the role of sphingosine 1-phosphate and its receptors in high-density lipoprotein-induced stimulation of astroglial cell function.

Authors:  Enkhzol Malchinkhuu; Koichi Sato; Takeshi Muraki; Koichi Ishikawa; Atsushi Kuwabara; Fumikazu Okajima
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

4.  Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades.

Authors:  A Pébay; M Toutant; J Prémont; C F Calvo; L Venance; J Cordier; J Glowinski; M Tencé
Journal:  Eur J Neurosci       Date:  2001-06       Impact factor: 3.386

5.  Dual regulation of EDG1/S1P(1) receptor phosphorylation and internalization by protein kinase C and G-protein-coupled receptor kinase 2.

Authors:  Kenneth R Watterson; Evelyn Johnston; Claire Chalmers; Alexey Pronin; Simon J Cook; Jeffrey L Benovic; Timothy M Palmer
Journal:  J Biol Chem       Date:  2001-12-06       Impact factor: 5.157

6.  Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes.

Authors:  Tadimeti S Rao; Karen D Lariosa-Willingham; Fen-Fen Lin; Emma L Palfreyman; Naichen Yu; Jerold Chun; Michael Webb
Journal:  Brain Res       Date:  2003-11-14       Impact factor: 3.252

Review 7.  Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.

Authors:  Kumlesh K Dev; Florian Mullershausen; Henri Mattes; Rainer R Kuhn; Graeme Bilbe; Daniel Hoyer; Anis Mir
Journal:  Pharmacol Ther       Date:  2007-09-08       Impact factor: 12.310

8.  Induction of pro-angiogenic signaling by a synthetic peptide derived from the second intracellular loop of S1P3 (EDG3).

Authors:  Tamar Licht; Lilia Tsirulnikov; Hadas Reuveni; Talia Yarnitzky; Shmuel A Ben-Sasson
Journal:  Blood       Date:  2003-05-22       Impact factor: 22.113

9.  Sphingosine 1-phosphate induces the production of glial cell line-derived neurotrophic factor and cellular proliferation in astrocytes.

Authors:  Kazuo Yamagata; Motoki Tagami; Yasuyoshi Torii; Fumio Takenaga; Shigehisa Tsumagari; Shingo Itoh; Yukio Yamori; Yasuo Nara
Journal:  Glia       Date:  2003-01-15       Impact factor: 7.452

10.  PICK1 interacts with and regulates PKC phosphorylation of mGLUR7.

Authors:  K K Dev; Y Nakajima; J Kitano; S P Braithwaite; J M Henley; S Nakanishi
Journal:  J Neurosci       Date:  2000-10-01       Impact factor: 6.167

View more
  24 in total

1.  S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-α autoamplification.

Authors:  John R Teijaro; Sean Studer; Nora Leaf; William B Kiosses; Nhan Nguyen; Kosuke Matsuki; Hideo Negishi; Tadatsugu Taniguchi; Michael B A Oldstone; Hugh Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-19       Impact factor: 11.205

Review 2.  The role of glial cells in multiple sclerosis disease progression.

Authors:  Luke M Healy; Jo Anne Stratton; Tanja Kuhlmann; Jack Antel
Journal:  Nat Rev Neurol       Date:  2022-02-21       Impact factor: 44.711

Review 3.  Regulation of human glia by multiple sclerosis disease modifying therapies.

Authors:  Luke M Healy; Mackenzie A Michell-Robinson; Jack P Antel
Journal:  Semin Immunopathol       Date:  2015-08-11       Impact factor: 9.623

4.  The expression of neuronal sorting nexin 8 (SNX8) exacerbates abnormal cholesterol levels.

Authors:  Gillian Muirhead; Kumlesh K Dev
Journal:  J Mol Neurosci       Date:  2013-12-21       Impact factor: 3.444

5.  The S1P1 receptor-selective agonist CYM-5442 reduces the severity of acute GVHD by inhibiting macrophage recruitment.

Authors:  Qiao Cheng; Shoubao Ma; Dandan Lin; Yu Mei; Huanle Gong; Lei Lei; Yuanyuan Chen; Ye Zhao; Bo Hu; Yan Wu; Xiao Yu; Lixiang Zhao; Haiyan Liu
Journal:  Cell Mol Immunol       Date:  2014-08-04       Impact factor: 11.530

6.  Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations.

Authors:  Graham K Sheridan; Kumlesh K Dev
Journal:  Sci Rep       Date:  2014-05-23       Impact factor: 4.379

7.  The EBI2 signalling pathway plays a role in cellular crosstalk between astrocytes and macrophages.

Authors:  Aleksandra Rutkowska; Sinead A O'Sullivan; Isabelle Christen; Juan Zhang; Andreas W Sailer; Kumlesh K Dev
Journal:  Sci Rep       Date:  2016-05-11       Impact factor: 4.379

8.  The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures.

Authors:  Catherine O'Sullivan; Anna Schubart; Anis K Mir; Kumlesh K Dev
Journal:  J Neuroinflammation       Date:  2016-02-08       Impact factor: 8.322

9.  Fingolimod attenuates splenocyte-induced demyelination in cerebellar slice cultures.

Authors:  Adam J Pritchard; Anis K Mir; Kumlesh K Dev
Journal:  PLoS One       Date:  2014-06-09       Impact factor: 3.240

10.  Fractalkine shedding is mediated by p38 and the ADAM10 protease under pro-inflammatory conditions in human astrocytes.

Authors:  Sinead A O'Sullivan; Fabrizio Gasparini; Anis K Mir; Kumlesh K Dev
Journal:  J Neuroinflammation       Date:  2016-08-22       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.